Natco Pharma launches novel fixed-dose combination drug for colorectal, gastric cancer
Natco Pharma has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of 20 tablets in a bottle
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Colorectal Cancer | Gastric (Stomach) Cancer | Gastroenterology | Pharmaceuticals